SCIENTIFIC REPORTS

Received: 5 April 2018 Accepted: 26 March 2019 Published online: 11 April 2019

OPEN Diagnostic value of procalcitonin, **C-reactive protein and lactate** dehydrogenase in paediatric malignant solid tumour concurrent with infection and tumour progression

Fan Li, Weiling Zhang, Huimin Hu, Yi Zhang & Dongsheng Huang

Infection is a fatal complication in cancer patients that sometimes is not distinguished from tumour progression. We compared the diagnostic value of procalcitonin (PCT), C-reactive protein (CRP) and lactate dehydrogenase (LDH) in paediatric malignant solid tumour concurrent with infection and tumour progression. The 152 children enrolled were divided into infection and control groups. Each group was divided further into stable and progression groups. An intergroup comparison was made in terms of serum PCT, CRP and LDH in all children. PCT, CRP and LDH levels were significantly higher in the infection than in the control groups (P < 0.05). Among the controls, PCT, CRP and LDH levels were significantly higher in the progression than in the stable groups (P < 0.05). In diagnosing infection, the sensitivity and specificity of PCT and CRP at the cutoff values of 0.296 ng/mL and 28.13 mg/L were relatively better than those at 0.5 ng/mL and 10 mg/L, respectively. LDH had the highest correlation with tumour progression, whereas PCT had the lowest (LDH, r = 0.684; CRP, r = 0.570; PCT, r = 0.322). Thus, PCT has the highest value in diagnosing infection and is less susceptible to tumour progression than CRP. LDH has obvious advantages in judging tumour progression.

Paediatric malignant solid tumour has become an important aetiologic factor of children's death throughout the world. Patients who receive long-term chemotherapy are prone to suffer concomitant life-threatening infections due to febrile neutropaenia, causing a rapid exacerbation in patient's conditions and resultant increased mortality rate¹⁻³. Therefore, in children, the detection and treatment of tumour concomitant with infection in the early phase of the illness help to control the patient's conditions and further improve prognosis. Traditional infection criteria, such as bacterial and viral cultures, have disadvantages of long detection times and relatively low sensitivity^{4,5}. Patients often miss the best time for infection treatment because of lack of an aetiological basis. C-reactive protein (CRP) is an acute phase protein and a sensitive biomarker that reflects the body's inflammatory reaction⁶. It considerably shortens the time window from onset to treatment because of the convenience in sampling and short detection time, so it has been used widely for infection diagnosis. In infection patients, their CRP level often is susceptible to multiple factors, such as cancer, anti-inflammatory medication and perioperative period⁷⁻¹⁰, and sometimes it is difficult to judge when the detection results fluctuate greatly. Procalcitonin (PCT) is an inactive propeptide substance of calcitonin. As a systemic inflammatory reaction indicator, it is superior to other inflammatory indicators in the judgement of bacterial infection¹¹⁻¹³. Existing studies have shown that its concentration is not susceptible to the impacts of immunodeficiency and use of corticosteroids^{14,15}, but whether it is susceptible to tumour factors remains unclear. Lactate dehydrogenase (LDH), as a glycolytic ferment, is present in the cytoplasm of almost all histiocytes. Its level is closely associated with infectious diseases and tumour diseases, and an

Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University., Beijing, (100730), China. Fan Li and Weiling Zhang contributed equally. Correspondence and requests for materials should be addressed to D.H. (email: hds5180@sina.com)

	Infection group	Control group	Statistic value	P value
Number of patients	34	118		
Age [years, M(Q)]	3(2.1)	3(4.0)		0.279
Gender [n (%)]				•
Male	16 (47.1)	75 (63.6)	$\chi^2 = 2.991$	0.084
Female	18 (52.9)	43 (36.4)	$\chi^{-} = 2.991$	
Tumour state [n (%)]		·		
Stable	20 (58.8)	74 (62.7)	$\chi^2 = 0.169$	0.681
Progression	14 (41.2)	44 (37.3)	$\chi^{-}=0.169$	
Tumour types [n (%)]		*		
Neuroblastoma	10 (29.4)	41 (34.7)		0.847
Hepatoblastoma	7 (20.6)	27 (22.9)	$\chi^2 = 8.304$	
Nephroblastoma	7 (20.6)	15 (12.7)		
Rhabdomyosarcoma	4 (11.8)	14 (11.9)		
PNET/Ewing's sarcoma	2 (5.9)	6 (5.1)		
Endodermal sinus tumour	1 (2.9)	3 (2.5)		
Langerhans cell histiocytosis	1 (2.9)	3 (2.5)		
Lymphoma	0 (0)	3 (2.5)		
Osteosarcoma	1 (2.9)	1 (0.8)		
Yolk sac tumour	0 (0)	2 (1.7)		
Pulmonary blastoma	0 (0)	1 (0.8)	1	
Pancreatoblastoma	1 (2.9)	0 (0)]	
Malignant germ cell tumour	0 (0)	1 (0.8)		
Clear cell sarcoma of the kidney	0 (0)	1 (0.8)	1	
Other factors [n (%)]		÷		
Perioperative period	7 (20.6)	17 (14.4)	$\chi^2 = 0.759$	0.384
Non-perioperative period	27 (79.4)	101 (85.6)	$\chi = 0.759$	

 Table 1. Comparison of general data (age, sex, state of tumour, tumour types and other factors) in children with malignant solid tumour between infection and control groups.

Group	Number of cases	PCT(ng/mL)	CRP(mg/L)	LDH(U/L)
Infection group	34	0.67(1.33)	97.00(88.12)	319.0(450.0)
Control group	118	0.08(0.07)	1.99(11.50)	282.5(116.0)
Statistic value	-	Z = -8.813	Z = -7.711	Z = -2.934
P value	-	0.000	0.000	0.003

Table 2. Comparison of PCT, CRP and LDH levels between infection and control groups [M(Q)].

.....

increased level may be related with tissue damages caused by infection or tumour cells^{16–18}. Previous studies have shown that increased LDH may be interpreted as reflecting high tumour burden or tumour aggressiveness, and dynamic changes in LDH level may be useful to predict prognosis in cancer patients¹⁹. We detected PCT, CRP and LDH in children's serum specimens, investigated their correlation with infection and tumour progression and further provided evidence for identification of paediatric malignant solid tumour concurrent with infection and tumour progression.

Results

General data. Comparison of general data (age, sex, state of tumour, tumour types and other factors) in children with malignant solid tumour showed no statistical difference between the infection and control groups (P > 0.05; Table 1).

Serum PCT, CRP and LDH levels and positive rates of PCT and CRP. Serum PCT, CRP and LDH levels and positive detection rates of PCT and CRP were significantly higher (P < 0.05 and P < 0.05, respectively) in the infection than in the control groups (Tables 2 and 3).

Serum PCT, CRP and LDH levels between the stable and progression groups among the infection and control groups. In the infection group, there was no significant difference in terms of PCT and CRP levels between the stable and progression groups (P > 0.05), but serum LDH levels were statistically significantly increased in the progression group (P < 0.05). In the control group, serum PCT, CRP and LDH levels were statistically significantly increased in the progression compared with those in the stable groups (P < 0.05; Table 4).

Group	Number of cases	РСТ	CRP
Infection group	34	26(76.5%)	32(94.1%)
Control group	118	0(0%)	31(26.3%)
Statistic value	—	$\chi^2 = 108.85$	$\chi^2 = 50.06$
P value	_	0.000	0.000

Table 3. Number of cases and positive rates of PCT and CRP between infection and control groups [n (%)].

Group	Subgroup	Number of cases	PCT(ng/mL)	CRP(mg/L)	LDH(U/L)
	Stable group	20	0.90(1.37)	109.50(107.94)	308.0(119.0)
Infection group	Progression group	14	0.52(1.32)	57.01(92.49)	606.0(2148.0)
	Statistic value	—	Z=0.840	Z=1.102	Z = -2.170
	P value	—	0.416	0.274	0.030
	Stable group	74	0.07(0.06)	0.94(2.16)	256.0(81.0)
Control group	Progression group	44	0.11(0.08)	12.99(28.26)	370.0(242.0)
	Statistic value	—	Z = -3.487	Z = -6.161	Z = -7.397
	P value	_	0.000	0.000	0.000

Table 4. Serum PCT, CRP and LDH levels between the stable and progression groups among the infection and control groups [M(Q)].




Figure 1. ROC curve of PCT, CRP and LDH in diagnosing infection and tumour progression in children with malignant solid tumour. (**a**) In diagnosing infection, the area under the ROC curve was 0.997 (95% CI, 0.992~1.000), 0.935 (95% CI, 0.895~0.974) and 0.665 (95% CI, 0.557~0.774) for PCT, CRP and LDH, respectively. (**b**) In diagnosing tumour progression, the area under the ROC curve was 0.692 (95% CI, 0.590~0.795), 0.840 (95% CI, 0.768~0.912) and 0.908 (95% CI, 0.853~0.963) for PCT, CRT and LDH, respectively.

Value of PCT, CRP and LDH in diagnosing infection in children with malignant solid tumour. The receiver operating characteristic (ROC) curve of serum PCT, CRP and LDH was drawn for all children (Fig. 1). The area under the ROC curve was 0.997 (95% confidence interval [CI], 0.992~1.000), 0.935 (95% CI, 0.895~0.974) and 0.665 (95% CI, 0.557~0.774) for PCT, CRP and LDH, respectively. Sensitivity/specificity values were 76.5%/100% and 94.1%/97.5% for PCT cutoff values of 0.5 and 0.296 ng/mL, respectively, and 94.1%/73.7% and 88.2%/87.3% when CRP cutoff values were 10 and 28.13 mg/L, respectively (Table 5).

Value of PCT, CRP and LDH in diagnosing tumour progression in children with malignant solid tumour. The ROC curve of serum PCT, CRP and LDH was drawn for children in the control group (Fig. 1). The area under the ROC curve was 0.692 (95% CI, 0.590~0.795), 0.840 (95% CI, 0.768~0.912) and 0.908 (95% CI, 0.853~0.963) for PCT, CRP and LDH, respectively. Sensitivity/specificity was 70.5%/70.3% for PCT cutoff values of 0.094; 52.3%/89.2% and 75.0%/73.0% for CRP cutoff values of 10 and 2.2 mg/L, respectively and 81.8%/79.7% and 77.3%/82.4% for LDH cutoff values of 295 and 300.5 U/L, respectively (Table 5).

PCT (ng/mL) ≥0.5 ≥0.296 ≥0.377 Sensitivity 76.5% 94.1% 88.2% 0.997 Specificity 100% 97.5% 100% 0.935 CRP (mg/L) ≥10 ≥28.13 ≥168.18 0.935 Specificity 73.7% 87.3% 100% 0.935 Specificity 73.7% 87.3% 100% 0.935 Specificity 73.7% 87.3% 100% 0.665 Sensitivity 60.2% 100% 0.665 Specificity 100% 99.7% 1 PCT combined with CRP (in series) 60.2% 100% 9.94 Specificity 100% 99.3% 1 9.96 Specificity 100% 99.3% 1 9.96 Specificity 73.7% 85.1% 1 10.92 Specificity 70.3% 10.6% 10.692 1.692 Specificity 70.3% 10.0% 1.692 1.692 Specificity		Standard cutoff value	Optimal cutoff value	Cutoff at 100% specificity	Area under ROC curve	
Sensitivity 76.5% 94.1% 88.2% 0.997 Specificity 100% 97.5% 100% CRP (mg/L) ≥ 10 ≥ 28.13 ≥ 168.18 0.935 Specificity 73.7% 87.3% 100% 0.935 Specificity 73.7% 87.3% 100% 0.935 Specificity 73.7% 87.3% 100% 0.935 Specificity 70.6% 11.8% 0.935 Specificity 70.6% 11.8% 0.665 Specificity 70.6% 11.8% 0.665 Specificity 70.6% 83.0% 5.96 PCT combined with CRP (in parallel) 99.7% 0.065 Specificity 73.7% 85.1% 0.996 Specificity 73.7% 85.1% 0.692 Specificity 70.3% 13.6% 6.92 Specificity 70.3% 10.0% 0.94 Specificity 2.10 $\geq 2.83.3$ 0.908 Specificity	Diagnosis of infection in all children					
Specificity 100% 97.5% 100% CRP (mg/L) ≥ 10 ≥ 28.13 ≥ 168.18 0.935 Sensitivity 94.1% 88.2% 11.8% 0.935 Specificity 73.7% 87.3% 100% 0.665 Sensitivity 70.6% 11.8% 0.665 Specificity 60.2% 100% 9.7% PCT combined with CRP (in series) 0.665 Specificity 100% 99.7% 0.996 Specificity 72.0% 83.0% 0.996 Specificity 73.7% 85.1% 0.996 Specificity 73.7% 85.1% 0.996 Specificity 73.7% 85.1% 0.996 Specificity 73.7% 85.1% 0.996 Specificity 73.7% 85.1% 0.996 Specificity 73.5% 13.6% 0.692 9.92	PCT (ng/mL)	≥ 0.5	≥0.296	≥0.377		
CRP (mg/L) ≥ 10 ≥ 28.13 ≥ 168.18 $_{0.935}$ Sensitivity 94.1% 88.2% 11.8% $_{0.935}$ Specificity 73.7% 87.3% 100% $_{0.665}$ Sensitivity 70.6% 11.8% $_{0.665}$ Specificity 60.2% 100% $_{0.665}$ Specificity 72.0% 83.0% $_{0.996}$ Sensitivity 72.0% 83.0% $_{0.996}$ Specificity 100% 99.7% $_{0.996}$ Specificity 73.7% 85.1% $_{0.996}$ Specificity 73.7% 85.1% $_{0.996}$ Specificity 73.7% 85.1% $_{0.996}$ Specificity 73.7% 85.1% $_{0.996}$ Specificity 70.7% 85.1% $_{0.996}$ Specificity 70.7% 85.1% $_{0.996}$ Specificity 82.3% 75.0% 22.2 $_{238.3}$ Specificity 89.2% 73.0% 100% <t< td=""><td>Sensitivity</td><td>76.5%</td><td>94.1%</td><td>88.2%</td><td>0.997</td></t<>	Sensitivity	76.5%	94.1%	88.2%	0.997	
Sensitivity 94.1% 88.2% 11.8% 0.935 Specificity 73.7% 87.3% 100% 100% LDH (U/L) ≥298.5 ≥2610 60.2% 100% Sensitivity 60.2% 100% 60.65 60.2% 100% PCT combined with CRP (in series) 60.2% 100% 9.94% 60.2% 100% Specificity 100% 99.7% 1 60.2% 100% 9.94% Sensitivity 72.0% 83.0% 1 50.95% 1 60.2% 100% 9.94% 60.2% 1.8% 60.5% 9.94% 1 9.94% 1 9.94% 1	Specificity	100%	97.5%	100%		
Specificity 73.7% 87.3% 100% LDH (U/L) 298.5 2610 0.665 Sensitivity 70.6% 11.8% 0.665 Specificity 60.2% 100% PCT PCT combined with CRP (in series) 60.2% 100% PCT Specificity 100% 99.7% 1 PCT Specificity 100% 99.7% 1 PCT Specificity 100% 99.7% 1 PCT Specificity 73.7% 85.1% 1 PCT Specificity 73.7% 85.1% 1 PCT Specificity 73.7% 85.1% 1 PCT Diagnosis of progression in uninfected tildren PCT (ng/mL) 20.094 20.252 PCT Specificity 70.3% 13.6% 0.692 PCT PCT (ng/mL) 210 22.2 238.3 PS PS PS PCT PCT PCT PCT PCT PCT PCT PCT PS	CRP (mg/L)	≥ 10	≥28.13	≥168.18		
LDH (U/L) ≥ 298.5 ≥ 2610 $_{0.665}$ Sensitivity 70.6% 11.8% $_{0.665}$ Specificity 60.2% 100% $_{0.996}$ PCT combined with CRP (in series) 83.0% $_{0.996}$ Specificity 100% 99.7% $_{0.996}$ PCT combined with CRP (in parallel) $_{0.93\%}$ $_{0.996}$ Sensitivity 98.6% 99.3% $_{0.996}$ Specificity 73.7% 85.1% $_{0.996}$ Diagnosis of progression in uninfected -hildren $_{0.094}$ ≥ 0.252 Sensitivity 20.094 ≥ 0.252 $_{0.692}$ Specificity 70.5% 13.6% $_{0.692}$ Specificity 210 ≥ 2.2 ≥ 38.3 $_{0.692}$ Specificity 89.2% 73.0% 100% $_{0.692}$ Specificity 89.2% 73.0% 100% $_{0.692}$ LDH (U/L) ≥ 295 ≥ 300.5 ≥ 391.5 $_{0.840}$ Specificity <t< td=""><td>Sensitivity</td><td>94.1%</td><td>88.2%</td><td>11.8%</td><td>0.935</td></t<>	Sensitivity	94.1%	88.2%	11.8%	0.935	
Sensitivity 70.6% 11.8% 0.665 Specificity 60.2% 100% 60.5% PCT combined with CRP (in series) 83.0% 2 $\end{tabular}$ Specificity 100% 99.7% 2 $\end{tabular}$ Specificity 100% 99.7% 2 $\end{tabular}$ PCT combined with CRP (in parallel) 2 2 $\end{tabular}$ Specificity 73.7% 85.1% 2 $\end{tabular}$ Diagnosis of progression in uninfected-bildren $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ PCT (ng/mL) $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ Specificity 70.5% 13.6% $\end{tabular}$ $\end{tabular}$ Specificity $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ Specificity \$2.3% 73.0% 100% $\end{tabular}$ LDH (U/L) $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ $\end{tabular}$ Specificity 79.7% </td <td>Specificity</td> <td>73.7%</td> <td>87.3%</td> <td>100%</td> <td></td>	Specificity	73.7%	87.3%	100%		
Specificity 60.2% 100% PCT combined with CRP (in series) 72.0% 83.0% 90.0% Sensitivity 72.0% 83.0% 90.0% 90.0% Specificity 100% 99.7% 100% 90.0% PCT combined with CRP (in parallel) 100% 90.0% 100% Specificity 73.7% 85.1% 100% 90.094 20.252 13.6% 0.692 Specificity 70.3% 13.6% 0.692 100% 20.252 238.3 100% Specificity 70.3% 100%<	LDH (U/L)		≥298.5	≥2610		
PCT combined with CRP (in series) Image: Combined with CRP (in series) Image: Combined with CRP (in parallel) Image: Combin	Sensitivity		70.6%	11.8%	0.665	
Sensitivity 72.0% 83.0% Image: constraint of the sensitivity 90.0% Image: constraint of the sensitivity 90.0% Image: constraint of the sensitivity 90.0% 20.252 90.0% 20.252 90.0% 20.	Specificity		60.2%	100%		
Specificity 100% 99.7% Image: Construct of the section of the sect	PCT combined with CRP (in series)					
PCT combined with CRP (in parallel)Image: comb	Sensitivity	72.0%	83.0%			
PCT combined with CRP (in parallel) Image: constraint of the section of the sectin of the sectin of the section of the section of the section of	Specificity	100%	99.7%			
Specificity 73.7% 85.1% Image: constraint of the second seco	PCT combined with CRP (in parallel)				- 0.996	
Image: Diagnosis of progression in uninfected children ≥ 0.094 ≥ 0.252 PCT (ng/mL) ≥ 0.094 ≥ 0.252 Sensitivity 70.5% 13.6% 0.692 Specificity 70.3% 100% 0.692 CRP (mg/L) ≥ 10 ≥ 2.2 ≥ 38.3 0.692 Sensitivity 52.3% 75.0% 22.7% 0.840 Specificity 89.2% 73.0% 100% 0.908 LDH (U/L) ≥ 295 ≥ 300.5 ≥ 391.5 0.908 Specificity 81.8% 77.3% 38.6% 0.908 Specificity 79.7% 82.4% 100% 100% LDH combined with CRP (in series) 100% 100% 100% Specificity 97.8% 95.2% 100% 10.944 Specificity 91.3% 94.3% 100% 10.944 Specificity 91.3% 94.3% 100% 10.944 Specificity 91.3% 94.3% 100% 10.944 Specificity 71.1% 60.2% <td>Sensitivity</td> <td>98.6%</td> <td>99.3%</td> <td></td> <td></td>	Sensitivity	98.6%	99.3%			
PCT (ng/mL) ≥ 0.094 ≥ 0.252 Sensitivity70.5%13.6%0.692Specificity70.3%100%0.692CRP (mg/L) ≥ 10 ≥ 2.2 ≥ 38.3 Sensitivity52.3%75.0%22.7%0.840Specificity89.2%73.0%100%LDH (U/L) ≥ 295 ≥ 300.5 ≥ 391.5 Sensitivity81.8%77.3%38.6%0.908Specificity79.7%82.4%100%LDH combined with CRP (in series)11Sensitivity97.8%95.2%1Sensitivity91.3%94.3%1Specificity71.1%60.2%1Diagnosis of infection combined with tumor progression in all children1Combination of three indices (in series)in all childrenSensitivity57.1%71.4%0.885	Specificity	73.7%	85.1%			
Sensitivity 70.5% 13.6% 0.692 Specificity 70.3% 100% 0.692 CRP (mg/L) ≥ 10 ≥ 2.2 ≥ 38.3 0.840 Sensitivity 52.3% 75.0% 22.7% 0.840 Specificity 89.2% 73.0% 100% 0.840 LDH (U/L) ≥ 295 ≥ 300.5 ≥ 391.5 0.908 Specificity 79.7% 82.4% 100% 0.908 Specificity 79.7% 82.4% 100% 1.09% LDH combined with CRP (in series) 100% 1.00% 1.09% Specificity 97.8% 95.2% 1.09% .0944 Specificity 91.3% 94.3% 1.00% .0944 Specificity 91.3% 94.3% 1.00% .0944 Diagnosis of infection combined with tumor progression in all children 1.014 .0944 Diagnosis of infection combined with tumor progression in all children .0885 .0885 Sensitivity 57.1% 71.4%	Diagnosis of progression in uninfected	children	1	I		
Specificity 70.3% 100% CRP (mg/L) ≥ 10 ≥ 2.2 ≥ 38.3 Sensitivity 52.3% 75.0% 22.7% Specificity 89.2% 73.0% 100% LDH (U/L) ≥ 295 ≥ 300.5 ≥ 391.5 Sensitivity 81.8% 77.3% 38.6% 0.908 Specificity 79.7% 82.4% 100% 0.908 LDH combined with CRP (in series) 100% 100% 100% LDH combined with CRP (in series) 97.8% 95.2% 0.944 Specificity 97.8% 95.2% 0.944 LDH combined with CRP (in parallel) 91.3% 94.3% 0.944 Specificity 91.3% 94.3% 0.944 Specificity 71.1% 60.2% 0.944 Diagnosis of infection combined with turor progression in all childrent 0.885 Sensitivity 57.1% 71.4% 0.885	PCT (ng/mL)		≥0.094	≥0.252		
$\begin{array}{ c c c c c c } \hline CRP (mg/L) & \geq 10 & \geq 2.2 & \geq 38.3 \\ \hline Sensitivity & 52.3\% & 75.0\% & 22.7\% & 0.840 \\ \hline Specificity & 89.2\% & 73.0\% & 100\% & \\ LDH (U/L) & \geq 295 & \geq 300.5 & \geq 391.5 \\ \hline Sensitivity & 81.8\% & 77.3\% & 38.6\% & 0.908 \\ \hline Specificity & 79.7\% & 82.4\% & 100\% & \\ LDH combined with CRP (in series) & & & & \\ \hline Sensitivity & 42.8\% & 58.0\% & & \\ \hline Specificity & 97.8\% & 95.2\% & & \\ LDH combined with CRP (in series) & & & & \\ \hline Sensitivity & 91.3\% & 94.3\% & & \\ \hline Specificity & 71.1\% & 60.2\% & & \\ \hline Diagnosis of infection combined with tumor progression in all children \\ \hline Combination of three indices (in series) & & & \\ \hline Sensitivity & 57.1\% & 71.4\% & & \\ \hline \end{array}$	Sensitivity		70.5%	13.6%	0.692	
Sensitivity 52.3% 75.0% 22.7% 0.840 Specificity 89.2% 73.0% 100% 0.840 LDH (U/L) \geq 295 \geq 300.5 \geq 391.5 0.908 Specificity 81.8% 77.3% 38.6% 0.908 Specificity 79.7% 82.4% 100% 100% LDH combined with CRP (in series) 0.908 Specificity 97.8% 58.0% Specificity 97.8% 95.2% 0.944 LDH combined with CRP (in parallel) 0.944 Specificity 91.3% 94.3% Specificity 71.1% 60.2% Diagnosis of infection combined with tumor progression in all children Combination of three indices (in series) Sensitivity 57.1% 71.4%	Specificity		70.3%	100%	1	
Specificity 89.2% 73.0% 100% LDH (U/L) \geq 295 \geq 300.5 \geq 391.5 Sensitivity 81.8% 77.3% 38.6% 0.908 Specificity 79.7% 82.4% 100% 100% LDH combined with CRP (in series) Sensitivity 42.8% 58.0% Specificity 97.8% 95.2% LDH combined with CRP (in parallel) 91.3% 94.3% Sensitivity 91.3% 94.3% Specificity 71.1% 60.2% Diagnosis of infection combined with turor progression in all children	CRP (mg/L)	≥10	≥2.2	≥38.3		
$\begin{array}{ c c c c c c } LDH (U/L) & \geq 295 & \geq 300.5 & \geq 391.5 \\ \hline Sensitivity & 81.8\% & 77.3\% & 38.6\% & 0.908 \\ \hline Specificity & 79.7\% & 82.4\% & 100\% & \\ LDH combined with CRP (in series) & & & & \\ Sensitivity & 42.8\% & 58.0\% & & & \\ Specificity & 97.8\% & 95.2\% & & & \\ LDH combined with CRP (in \\ parallel) & & & & \\ Sensitivity & 91.3\% & 94.3\% & & \\ Specificity & 71.1\% & 60.2\% & & \\ \hline Diagnosis of infection combined with turor progression in all children \\ \hline Combination of three indices (in \\ series) & & \\ \hline Sensitivity & 57.1\% & 71.4\% & 0.885 \\ \hline \end{array}$	Sensitivity	52.3%	75.0%	22.7%	0.840	
Sensitivity 81.8% 77.3% 38.6% 0.908 Specificity 79.7% 82.4% 100% 100% LDH combined with CRP (in series) Sensitivity 42.8% 58.0% Specificity 97.8% 95.2%	Specificity	89.2%	73.0%	100%	-	
Specificity 79.7% 82.4% 100% LDH combined with CRP (in series) Sensitivity 42.8% 58.0% Specificity 97.8% 95.2%	LDH (U/L)	≥295	≥300.5	≥391.5		
LDH combined with CRP (in series)Image: Combined with combined with tumor progression in all childrenCombination of three indices (in series)Image: Combined with combined w	Sensitivity	81.8%	77.3%	38.6%	0.908	
Sensitivity42.8%58.0%Image: Sensitivity97.8%95.2%Image: Sensitivity97.8%95.2%Image: Sensitivity91.3%94.3%Image: Sensitivity91.3%94.3%Image: Sensitivity91.3%94.3%Image: Sensitivity91.3%94.3%Image: Sensitivity0.944Sensitivity91.3%94.3%Image: Sensitivity0.944Image: Sensitivity0.944Diagnosis of infection combined with tumor progression in all childrenImage: Sensitivity0.944Combination of three indices (in series)Image: Sensitivity0.885Sensitivity57.1%71.4%Image: Sensitivity	Specificity	79.7%	82.4%	100%		
Specificity97.8%95.2%0.944LDH combined with CRP (in parallel)91.3%94.3%0.944Sensitivity91.3%94.3%0.944Specificity71.1%60.2%0.944Diagnosis of infection combined with tumor progression in all children0.944Combination of three indices (in series)0.945Sensitivity57.1%71.4%	LDH combined with CRP (in series)					
LDH combined with CRP (in parallel) 91.3% 94.3% 0.944 Sensitivity 91.3% 94.3% 0.944 Specificity 71.1% 60.2% 0.944 Diagnosis of infection combined with tumor progression in all children 0.944 0.944 Combination of three indices (in series) 0.885 0.885	Sensitivity	42.8%	58.0%			
In Frombined with CKP (in parallel) 91.3% 94.3% Sensitivity 91.3% 94.3% Specificity 71.1% 60.2% Diagnosis of infection combined with tumor progression in all children Combination of three indices (in series) Sensitivity 57.1% 71.4%	Specificity	97.8%	95.2%		1	
Specificity 71.1% 60.2% Diagnosis of infection combined with tumor progression in all children Combination of three indices (in series) Sensitivity 57.1% 71.4%	LDH combined with CRP (in parallel)	0.944				
Diagnosis of infection combined with tumor progression in all children Combination of three indices (in series) Sensitivity 57.1% 71.4%	Sensitivity	91.3%	94.3%		1	
Combination of three indices (in series) Image: Combination of three indices (in series) Sensitivity 57.1% 71.4% 0.885	Specificity	71.1%	60.2%]	
series) 0.885 Sensitivity 57.1% 71.4% 0.885	Diagnosis of infection combined with tumor progression in all children					
Sensitivity 57.1% 71.4%	Combination of three indices (in series)					
Specificity 91.3% 93.5%	Sensitivity	57.1%	71.4%		0.885	
	Specificity	91.3%	93.5%		1	

Table 5. Sensitivity and specificity at different cutoff values in separate or combined diagnosis.

.....

Value of PCT, CRP and LDH in combined diagnosis. The ROC curve of PCT combined with CRP in diagnosing infection, LDH combined with CRP in diagnosing tumour progression, and the combination of three indices in diagnosing infection with tumour progression were drawn, respectively (Fig. 2). The area under the ROC curve was 0.996 (95% CI, 0.990~1.000), 0.944 (95% CI, 0.901~0.987) and 0.885 (95% CI, 0.817~0.952) for PCT combined with CRP, LDH combined with CRP and the combination of three indices, respectively. Sensitivity/specificity was 72.0%/100% and 98.6%/73.7% for PCT combined with CRP in series and parallel methods (PCT \geq 0.5 ng/mL and CRP \geq 10 mg/L), respectively; 42.8%/97.8% and 91.3%/71.1% for LDH combined with CRP in series and parallel methods (LDH \geq 295 U/L and CRP \geq 10 mg/L), respectively and 57.1%/91.3% for combination of three indices in series method (PCT \geq 0.5 ng/mL, CRP \geq 10 mg/L, and LDH \geq 295 U/L) (Table 5).

Correlation analysis of serum PCT, CRP and LDH with infection and tumour progression. PCT, CRP and LDH levels were positively correlated with infection (PCT, r = 0.717, P = 0.000; CRP, r = 0.628, P = 0.000; LDH, r = 0.239, P = 0.003); PCT had the highest and LDH the lowest correlation. Serum PCT, CRP and LDH levels were positively correlated with tumour progression (PCT, r = 0.322, P = 0.000; CRP, r = 0.570, P = 0.000; LDH, r = 0.684, P = 0.000); LDH had the highest and PCT the lowest correlation.

Discussion

Infection is the most common and one of the most fatal complications during long-term chemotherapy in children with malignant solid tumour. Early diagnosis and treatment of infection facilitate control of the patient's




Figure 2. ROC curve of combined detection in diagnosing infection and tumour progression in children with malignant solid tumour. (**a**) In the diagnosis of infection by PCT combined with CRP, the area under the ROC curve was 0.996 (95% CI, 0.990~1.000). (**b**) In the diagnosis of tumour progression by LDH combined with CRP, the area under the ROC curve was 0.944 (95% CI, 0.901~0.987). (**c**) In the diagnosis of infection with tumour progression by combination of three indices, the area under the ROC curve was 0.885 (95% CI, 0.817~0.952).

conditions and improve prognosis. In cancer patients treated with myelosuppressive chemotherapy, infection often shows lack of corresponding inflammatory symptoms and signs due to the chemotherapy-induced neutropaenia¹, with no increase in body temperature and no easy tendency to form infectious foci, such as suppuration at infection sites, so that patients often are misdiagnosed. CRP is a common clinically used infection diagnosis biomarker that is rapid and inexpensive and may be a good partner to refine the diagnosis of infection²⁰. Nonetheless, neoplastic fever often is accompanied by increased CRP, so that it may not be distinguished from infection fever²¹. Early empirical antibacterial therapy often leads to fungal infection and produces antimicrobial resistance²². In children with malignant solid tumour accompanied by early infection, a sensitive and specific infection diagnosis method is vital to improve survival rate and prognosis. Recent studies have indicated that, as an inactive propeptide substance of calcitonin and an indicator for systemic inflammatory reaction, PCT has a high specificity and sensitivity and is superior to other inflammatory factors in the diagnosis of bacterial infection, and its concentration is not susceptible to immunodeficiency conditions and use of corticosteroids; its diagnostic value has been significantly superior to CRP and other cytokines¹¹⁻¹⁵. In addition, recent studies also have indicated that LDH is closely associated with infectious and tumour diseases, and increased LDH level may be related to tissue damages caused by infection or tumour cells¹⁶⁻¹⁸, so that LDH detection and analysis in children with tumour progression plus infection also can provide some evidence for clinical differentiation. The combined detection of serum CRP, PCT and LDH provides a new idea for diagnosis of children with malignant solid tumour and infection and further guides the clinical treatment in a better manner.

We detected PCT, CRP and LDH in serum specimens of children and investigated their correlation with infection and tumour progression. The serum PCT, CRP and LDH levels and positive detection rates of PCT and CRP were significantly higher (P < 0.05 and P < 0.05, respectively) in the infection than in the control groups. Therefore, PCT and CRP can serve as infective indicators for diagnosis of paediatric tumour with infection. The area under the ROC curves for PCT, CRP and LDH showed that PCT was superior to CRP and that LDH did not show much value in terms of infection diagnosis. Additional studies indicated relatively low (76.5%) sensitivity and relatively good (100%) specificity at a PCT cutoff value of 0.5 ng/mL and relatively good sensitivity/specificity (94.1%/97.5%) at a cutoff value of 0.296 ng/mL. Therefore, we deduced that using 0.3 ng/mL as the threshold value for diagnosing infection in children with malignant tumour seemed reliable. The reason might be related with age, immunosuppression, tumour factors or other nonspecific factors and also with the small sample size. The sample size will be expanded, or multicentre studies will be performed for further validation.

Our study also found relatively good (94.1%) sensitivity and relatively low (73.7%) specificity at a CRP cutoff value of 10 mg/L and relatively good sensitivity/specificity (88.2%/87.3%) at a cutoff of 28.13 mg/L. Some studies have indicated that CRP level is positively correlated with tumour progression²³. Therefore, considering the impact of tumour factors, we also deduced that using 25 to 30 mg/L as the threshold value in children with solid tumour seemed more reliable when diagnosing infection, and a prospective study should be conducted for further validation.

Regarding the relationship between these three markers and tumour progression, in the control group, PCT, CRP and LDH levels were significantly higher in the progression than in the stable groups, which indicated that the levels of the three markers were affected by tumour progression. However, in the infection group, LDH levels were significantly increased in the progression compared with those in the stable groups, and there was no significant difference in PCT and CRP levels between these groups. It may be that PCT and CRP levels were significantly affected by the infection factors and, thus, led to no difference in results. LDH levels were less affected by infection, which suggested that LDH levels in the two groups were significantly different. The results were in line with expectations. To avoid the influence of infection factors, we performed ROC curves on PCT, CRP and LDH in the control group. The area under the ROC curve was 0.693 (95% CI, 0.591~0.795), 0.837 (95% CI, 0.764~0.910) and

0.908 (95% CI, 0.853~0.963), respectively. Sometimes, when unexplained increases in CRP and LDH were found in non-infected patients, clinicians often needed to consider whether it was caused by a definite tumour progression, so this study chose the cutoff values at 100% specificity and relatively highest sensitivity as a reference. When the PCT, CRP and LDH cutoff value was greater than 0.252 ng/mL, 38.3 mg/L and 391.5 U/L, respectively, 100% of non-infected patients had tumour progression.

This study established a combined diagnosis model. PCT combined with CRP was used for the diagnosis of infection, LDH combined with CRP was used for the diagnosis of tumour progression in non-infected children, and the combination of three indices were used for the diagnosis of infection combined with tumour progression. In the combined diagnosis, the series method improved the specificity, while the parallel method improved the sensitivity. We found that the parallel method was more reliable in the combined diagnosis of infection, and the optimal cutoff was 0.296 ng/mL and 28.13 mg/L for PCT and CRP, respectively. When LDH and CRP were combined to diagnose tumour progression, the parallel method was also better, and the optimal cutoff was 295 U/L and 10 mg/L for LDH and CRP, respectively. Considering that the parallel method has no practical application value when using the combination of three indices in diagnosis. Sensitivity and specificity was relatively better at the cutoff of 0.296 ng/mL, 28.13 mg/L for PCT, CRP and LDH, respectively. The results showed that sensitivity and specificity could be improved by selecting the appropriate method for combined diagnosis, which was helpful for the differentiation of infection from tumour progression in children with malignant tumour.

Analysis indicated that their PCT, CRP and LDH levels were positively correlated with infection (PCT, r=0.717, P=0.000; CRP, r=0.628, P=0.000; LDH, r=0.239, P=0.003), with PCT and CRP having a relatively high and LDH a relatively low correlation. Serum PCT, CRP and LDH levels were positively correlated with tumour progression; LDH had the highest and PCT the lowest correlation. Analysis of these results indicated that PCT and CRP had significantly higher values than LDH in diagnosing infection, and LDH and CRP also had significant advantages in judging tumour progression. Despite the positive correlation with tumour progression, PCT was less impacted by the tumour itself, so there was almost no significance when using it to judge tumour progression.

In summary, our results indicated that serum PCT and CRP are important indicators in diagnosing infection in children with malignant solid tumour. PCT is superior to CRP in diagnosing infection, and it is significantly less susceptible to tumour factors than CRP. LDH and CRP have obvious advantages in judging whether the tumour has progressed compared with PCT. The combined detection of PCT, CRP and LDH is of high diagnostic value in identifying paediatric malignant solid tumour concurrently with infection and tumour progression and is helpful in the early detection of tumour conditions. Therefore, combined detection provides the basis for the early and reasonable implementation of clinical treatment.

Materials and Methods

Clinical materials. This study was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University. All research was performed in accordance with relevant regulations, and informed consent was approved from the children and their parents. The study enrolled 152 children with malignant solid tumour admitted into the Paediatric Department of Beijing TongRen Hospital from March 2016 to March 2017. There were 51 cases of neuroblastoma, 34 of hepatoblastoma, 22 of nephroblastoma, 18 of rhabdomyosarcoma, 8 of PNET/Ewing's sarcoma, 4 of endodermal sinus tumour, 4 of Langerhans cell histiocytosis, 3 of lymphoma, 2 of osteosarcoma, 2 of yolk sac tumour and 1 each of pulmonary blastoma, pancreatoblastoma, malignant germ cell tumour and clear cell sarcoma of the kidney (Table 1). All children were divided into infection (34 cases) and control (without infection, 118 cases) groups. Of 34 children in the infection group who had nosocomial bacterial or bacterial and viral infections, 23 had lower respiratory, 9 catheter-associated and 2 urinary tract infections. The 34 children in the control group were subdivided into stable tumour (74) and tumour progression (14) groups. All serum specimens were collected before the start of the chemotherapy cycle, and children who had taken antibiotics and corticosteroids were ruled out.

Diagnosis criteria of tumour and infection. All malignant solid tumours were pathologically diagnosed by pathological biopsy or surgical resection. The judgement criteria for tumour progression were a 25% increase in one or more measurable lesions and appearance of new lesions²⁴. The infection was diagnosed according to the definitions of the Centers for Disease Control and Prevention (CDC)²⁵.

Methods

This study was approved by the hospital's Ethic Committee, and the informed consent was approved from the patients and their legal guardians. All experiments were performed in accordance with relevant guidelines and regulations. All children had 4 mL fasting venous blood collected before chemotherapy after admission. Serum PCT and routine biochemical tests (including CRP and LDH) were performed via the conventional detection methods at this hospital: electrochemiluminescence method to detect PCT, immunoturbidimetry to detect CRP and enzyme kinetics method to detect LDH. Infection results were judged according to PCT \geq 0.5 (positive) and <0.5 (negative) ng/mL²⁶⁻²⁸ and CRP \geq 10 (positive) and <10 (negative) mg/L^{20,29}. The normal reference range of serum LDH was 110–295 U/L. The sensitivity and specificity of the combined diagnosis were evaluated by both series and parallel methods. Diagnostic rule of series method: the combined diagnosis result is considered positive when the results of all individual assays are positive. Diagnostic rule of parallel method: the combined diagnosis result is considered positive when the result of any individual assay is positive.

Statistical analysis. The data were analysed statistically using the SPSS 22.0. Nonnormal distribution measurement data were expressed by the median (interquartile range) [M(Q)]. The nonparametric Mann–Whitney U test was adopted for the comparison, the χ^2 test was adopted for the enumeration data, Spearman's test was performed to analyse the correlation between the ranked data and the measurement data, and P < 0.05 indicated that the difference was statistically significant. The ROC curve of combined diagnosis was drawn according to the predicted probability after binary logistic regression analysis of PCT, CRP and LDH.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

- Crawford, J., Dale, D. C. & Lyman, G. H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. *Cancer.* 100, 228–237 (2004).
- Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E. & Lyman, G. H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. *Cancer.* 106, 2258–2266 (2006).
- 3. López-Pousa, A. *et al.* DELFOS Study Group. Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. *Eur J Cancer Care (Engl).* **19**, 648–655 (2010).
- 4. Lagier, J. C. et al. Current and past strategies for bacterial culture in clinical microbiology. Clin Microbiol Rev. 28, 208–236 (2015).
- Leland, D. S. & Ginocchio, C. C. Role of Cell Culture for Virus Detection in the Age of Technology. *Clin Microbiol Rev.* 20, 49–78 (2007).
- 6. Pepys, M. B. & Baltz, M. L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. *Adv Immunol.* **34**, 141–212 (1983).
- Jukic, T., Ihan, A. & Stubljar, D. Dynamics of inflammation biomarkers C-reactive protein, leukocytes, neutrophils, and CD64 on neutrophils before and after major surgical procedures to recognize potential postoperative infection. *Scand J Clin Lab Invest.* 75, 500–507 (2015).
- Shimizu, T., Ishizuka, M. & Kubota, K. The preoperative serum C-reactive protein level is a useful predictor of surgical site infections in patients undergoing appendectomy. Surg Today. 45, 1404–1410 (2015).
- 9. Bolayirli, M. et al. C-reactive protein as an acute phase protein in cancer patients. Med Oncol. 24, 338-344 (2007).
- 10. Nizri, E. et al. C-reactive protein as a marker of complicated diverticulitis in patients on anti-inflammatory medications. Tech Coloproctol. 18, 145-149 (2014).
- 11. Trimarchi, H. et al. Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires). 73, 411-416 (2013).
- Tanrıverdi, H. *et al.* Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. *Wien Klin Wochenschr.* 127, 756–763 (2015).
- 13. R Nath, S. *et al.* Comparative diagnostic test evaluation of serum procalcitonin and C-reactive protein in suspected bloodstream infections in children with cancer. *J Med Microbiol.* **66**, 622–627 (2017).
- 14. Rinaldi, S., Adembri, C., Grechi, S. & De Gaudio, A. R. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. *Crit Care Med.* 34, 2334–2339 (2006).
- 15. Hatzistilianou, M. *et al.* Serial procalcitonin responses in infection of children with secondary immunodeficiency. *Clin Invest Med.* **30**, E75–85 (2007).
- Ede, L. C., O'Brien, J., Chonmaitree, T., Han, Y. & Patel, J. A. Lactate dehydrogenase as a marker of nasopharyngeal inflammatory injury during viral upper respiratory infection: implications for acute otitis media. *Pediatr Res.* 73, 349–354 (2013).
- 17. Butt, A. A. et al. Serum LDH level as a clue to the diagnosis of histoplasmosis. AIDS Read. 12, 317-321 (2002).
- Jurisic, V., Radenkovic, S. & Konjevic, G. The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. Adv Exp Med Biol. 867, 115–124 (2015).
- 19. Zhang, J. et al. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 5, 9800 (2015).
- 20. Clyne, B. & Olshaker, J. S. The C-reactive protein. J Emerg Med. 17, 1019-1025 (1999).
- Kallio, R., Bloigu, A., Surcel, H. M. & Syrjälä, H. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer. 9, 124–128 (2001).
- 22. Averbuch, D. *et al.* European guidelines for empirical antibacterial therapy for febrile neuropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. *Haematologica*. **98**, 1826–1835 (2013). Erratum in: *Haematologica*. **99**, 400 (2014).
- Verma, G. R. et al. Thrombocytosis and Raised CRP Levels Predicts Advanced Stage in Esophageal Carcinoma. J Gastrointest Cancer. 46, 350–355 (2015).
- 24. Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer. 47, 207-214 (1981).
- Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C. & Hughes, J. M. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 16, 128–140 (1988).
- Lai, C. C. et al. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 61, 512–515 (2010).
- 27. Fazili, T., Endy, T., Javaid, W. & Maskey, M. Role of procalcitonin in guiding antibiotic therapy. *Am J Health Syst Pharm.* **69**, 2057–2061 (2012).
- Quenot, J. P. et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Int Care. 3, 21 (2013).
- Lelubre, C., Anselin, S., Zouaoui Boudjeltia, K., Biston, P. & Piagnerelli, M. Interpretation of C-Reactive Protein Concentrations in Critically III Patients. *Biomed Res Int.* 2013, 124021 (2013).

Acknowledgements

The authors sincerely thank Jing Li, Yuan Wen and Tao Han for their constructive suggestion and their support during the study. The authors also thank the funding support of the Beijing Economic-Technological Development Area Scientific and Technological Innovation Leading Talents Program. Beijing Economic-Technological Development Area Scientific and Technological Innovation Leading Talents Program (2015-21).

Author Contributions

Weiling Zhang contributed to the conception of the study and manuscript preparation; Fan Li designed experiments, performed the data analyses and wrote the manuscript; Huimin Hu, Yi Zhang and Dongsheng Huang helped perform the analysis with constructive discussions. All authors have reviewed and agreed to this information before submission.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019